Nicole White
Corporate Officer/Principal at ASSEMBLY BIOSCIENCES, INC.
Net worth: 194 723 $ as of 30/05/2024
Nicole White active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 16/11/2020 | - |
Career history of Nicole White
Former positions of Nicole White
| Companies | Position | Start | End |
|---|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | 30/04/2018 | 31/10/2020 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 30/09/2015 | 31/03/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 28/02/2009 | 30/09/2015 |
Training of Nicole White
| University of California, Irvine | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Nicole White
- Experience
